Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative 
colitis, according to new findings from an international phase III double-blind 
trial. The addition of this drug makes a ménage à trois of available 
drugs--comprising infliximab, adalimumab and golimumab--for the treatment of 
ulcerative colitis.